New pill shows promise for Tough-to-Treat blood cancers
NCT ID NCT04756726
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This early-stage trial tests a new oral drug called cemsidomide (CFT7455) in about 224 adults with non-Hodgkin's lymphoma or multiple myeloma that has returned or not responded to prior therapies. The study aims to find safe doses and check for side effects, both when the drug is used alone and, for myeloma patients, in combination with dexamethasone. It is not yet known if the drug will shrink tumors or improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Colorado Blood Cancer Institute (Sarah Cannon Research Institute)
Denver, Colorado, 80218, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University Hospital
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Phoenix, Arizona, 85054, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Mt Sinai Medical Center
New York, New York, 10029, United States
-
Tennessee Oncology (Sarah Cannon Research Institute)
Nashville, Tennessee, 37203, United States
-
University of California-San Francisco
San Francisco, California, 94143, United States
-
Washington University School of St. Louis
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cemsidomide (also called CFT7455), taken as a pill, sometimes with dexamethasone
What this could lead to
If it works, this could offer a new treatment option for people with blood cancers that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1/2) trial, so the drug may not work or may have serious side effects. It is only for people who have already tried other treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.